Sandra Rebouissou - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Sandra Rebouissou

Showing results (41-50 of 50) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 50 results.

JHEP Reports : Innovation in Hepatology|December 24, 2024

Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptorsCharlotte A Hernandez, Claire Verzeroli, Armando Andres Roca-Suarez, et al.

Science Translational Medicine|July 11, 2014

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotypeSandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, et al.

Nature Genetics|March 31, 2015

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsKornelius Schulze, Sandrine Imbeaud, Eric Letouzé, et al.

European Journal of Cancer (Oxford, England : 1990)|February 8, 2024

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survivalAurore Pire, Theo Z Hirsch, Guillaume Morcrette, et al.

Cancer Discovery|April 24, 2021

Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver CancerTheo Z Hirsch, Jill Pilet, Guillaume Morcrette, et al.

Hepatology (Baltimore, Md.)|June 18, 2019

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular CarcinomaJean-Charles Nault, Yoann Martin, Stefano Caruso, et al.

Nature Communications|January 18, 2019

Recurrent activating mutations of PPARγ associated with luminal bladder tumorsNatacha Rochel, Clémentine Krucker, Laure Coutos-Thévenot, et al.

Journal of Hepatology|December 1, 2025

Targeting ATR to overcome cisplatin resistance in hepatoblastomaPierre Morel-Ribeiro, Marianna Cornet, Jill Pilet, et al.

Gastroenterology|December 13, 2016

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant TransformationJean-Charles Nault, Gabrielle Couchy, Charles Balabaud, et al.

Hepatology (Baltimore, Md.)|July 18, 2018

Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular CarcinomaMarina Bárcena-Varela, Stefano Caruso, Susana Llerena, et al.

Pageof 5

Search research articles

Showing results (41-50 of 50) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 50 results.

JHEP Reports : Innovation in Hepatology|December 24, 2024

Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptorsCharlotte A Hernandez, Claire Verzeroli, Armando Andres Roca-Suarez, et al.

Science Translational Medicine|July 11, 2014

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotypeSandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, et al.

Nature Genetics|March 31, 2015

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsKornelius Schulze, Sandrine Imbeaud, Eric Letouzé, et al.

European Journal of Cancer (Oxford, England : 1990)|February 8, 2024

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survivalAurore Pire, Theo Z Hirsch, Guillaume Morcrette, et al.

Cancer Discovery|April 24, 2021

Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver CancerTheo Z Hirsch, Jill Pilet, Guillaume Morcrette, et al.

Hepatology (Baltimore, Md.)|June 18, 2019

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular CarcinomaJean-Charles Nault, Yoann Martin, Stefano Caruso, et al.

Nature Communications|January 18, 2019

Recurrent activating mutations of PPARγ associated with luminal bladder tumorsNatacha Rochel, Clémentine Krucker, Laure Coutos-Thévenot, et al.

Journal of Hepatology|December 1, 2025

Targeting ATR to overcome cisplatin resistance in hepatoblastomaPierre Morel-Ribeiro, Marianna Cornet, Jill Pilet, et al.

Gastroenterology|December 13, 2016

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant TransformationJean-Charles Nault, Gabrielle Couchy, Charles Balabaud, et al.

Hepatology (Baltimore, Md.)|July 18, 2018

Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular CarcinomaMarina Bárcena-Varela, Stefano Caruso, Susana Llerena, et al.

Pageof 5